Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Bioentrepreneur
  • Published:

A work in progress

Nature Biotechnology volume 30, pages 388–389 (2012)Cite this article

Subjects

In life sciences, a successful company very often looks markedly different from what was envisioned at founding.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Author information

Authors and Affiliations

  1. Bill Polvino is president and CEO at Veloxis Pharmaceuticals, Edison, New Jersey, USA.,

    Bill Polvino

Authors
  1. Bill Polvino
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bill Polvino.

Ethics declarations

Competing interests

B.P. is an employee with equity interest in Veloxis Pharmaceuticals.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Polvino, B. A work in progress. Nat Biotechnol 30, 388–389 (2012). https://doi.org/10.1038/nbt.2178

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.2178

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research